BEONE MEDICINES stated during a research survey that its product, Baiyueda, is currently being supplied by an external Contract Manufacturing Organization (CMO). All related processes are proceeding according to the established timeline.
The company anticipates the formal commercial launch of Baiyueda in the United States to occur between the end of the third quarter and the beginning of the fourth quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments